Literature DB >> 2540532

Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC).

A Depierre1, E Lemarie, G Dabouis, G Garnier, P Jacoulet, J C Dalphin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2540532

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  9 in total

1.  A phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, a Southwest Oncology Group study.

Authors:  C S Higano; J J Crowley; R V Veith; R B Livingston
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  New perspectives in lung cancer.5. New drugs in lung cancer.

Authors:  D C Talbot; I E Smith
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

3.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

4.  Efficacy of 5'-nor-anhydrovinblastine (vinorelbine), against freshly explanted clonogenic human tumor cells in vitro.

Authors:  I Djuanda; H Depenbrock; R Peter; T Block; G Pohlmann; J Rastetter; A R Hanauske
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 5.  Prevention and management of extravasation of cytotoxic drugs.

Authors:  G Bertelli
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

6.  Phase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children's Oncology Group study.

Authors:  John F Kuttesch; Mark D Krailo; Timothy Madden; Mary Johansen; Archie Bleyer
Journal:  Pediatr Blood Cancer       Date:  2009-10       Impact factor: 3.167

Review 7.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

8.  Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.

Authors:  P Comella; G Frasci; G De Cataldis; N Panza; R Cioffi; C Curcio; M Belli; A Bianco; G Ianniello; L Maiorino; M Della Vittoria; J Perchard; G Comella
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

9.  Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.

Authors:  K Gomi; H Ohno; K Nomura; M Okabe; K Kobayashi; H Niitani
Journal:  Jpn J Cancer Res       Date:  1992-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.